SCHEMBL25326482

SCHEMBL25326482

CC(C)COc1ccc(C=O)cc1C#N

nearest known ligand 0.59

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
XDH P47989 7/20 0.55
SLC22A12 Q96S37 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30902412 0.83 ALDH1A1 (0.55) XDH
SCHEMBL177342 0.81 FDPS (0.54)
SCHEMBL29445723 0.81 XDH (0.54) XDH
SCHEMBL28714428 0.81 XDH (0.54) XDH
SCHEMBL10088423 0.80 XDH (0.51) XDH
SCHEMBL30262368 0.80 FDPS (0.71)
SCHEMBL7034558 0.80 FDPS (0.71)
SCHEMBL31573 0.80 XDH (0.69) XDHSLC22A12
SCHEMBL2344031 0.78 XDH (0.53) XDHSLC22A12
SCHEMBL25327365 0.78 FDPS (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114105881-B Platelet aggregation inhibitor, and preparation method and application thereof 沈阳海诺威医药科技有限公司 2024-01-26 CN disclosed
EP-3960734-B1 PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) 2023-10-11 EP disclosed
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-08-01 US disclosed
CN-114105881-A Platelet aggregation inhibitor and preparation method and application thereof 沈阳海诺威医药科技有限公司 2022-03-01 CN disclosed
CN-102766099-B There is compound and salt, preparation method and the purposes of xanthine oxidase inhibitory activity SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2015-09-23 CN disclosed
CN-102766099-A Compound with xanthine oxidase inhibitory activity as well as salt, preparation methods and application thereof UNIV SHENYANG PHARMACEUTICAL 2012-11-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713300-B2 Platelet aggregation inhibitor, preparation and uses thereof TFPI, F12, TFPI2 XDH 413/4885SLC22A12 2481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.